RxDoctor Payments Data

Angela Toney, NP

Adult Health · Millsboro, DENPI 1306030358

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 100.0% of the total across 44 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 15 manufacturers reported payments, led by Lilly USA, LLC at 31.3% of the total. Reporting peaked in 2022 at $430 and has fallen 91.9% since, to $35 in 2024.

$911in general payments, 2019–2025

Across 44 payments — averaging $20.70 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Lilly USA, LLC$285
  • AbbVie$147
  • Sun Pharmaceutical Industries Inc.$93
  • Johnson & Johnson$75
  • Abbott$63
  • UCB, Inc.$45
  • plus $203 from 9 others

What the payments were for

  • Food & beverage$911100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$911 in reported general payments places this provider in the 65th percentile of 65 adult health providers in Delaware.

See all adult health providers in Delaware

Medicare billing

Part B allowed, 2024
$11,719
Medicare patients
40
Services billed
110

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MovantikNaloxegol Oxalate12$6,602
BelbucaBuprenorphine Hcl11$5,768
Oxycodone Hcl120$2,261
Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen47$1,454
Morphine Sulfate ErMorphine Sulfate51$974
Lidocaine13$954
Tramadol Hcl ErTramadol Hcl17$872
Morphine Sulfate28$636
Gabapentin34$519
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen28$432
Hydromorphone Hcl23$371
Pregabalin15$229
Tramadol Hcl25$110
Zolpidem Tartrate19$82
Tizanidine Hcl19$81

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Collegium Pharmaceutical, Inc.Belbuca$34$5,76811 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 65 adult health providers in Delaware.

Other adult health in Millsboro

See the full list for Delaware

Where these figures come from

Is this you, or does something look wrong? →